-
Study aim
-
In vivo fasted-state bioequivalence study of Tenofovir Alafenamide tablet
-
Design
-
The clinical trial has control and test groups with crossover, randomized design, without blinding. Twenty-four healthy volunteers will participate randomly in the study as two twelve-person study groups. To randomly assign participants in two groups, the lottery method will be used.
-
Settings and conduct
-
After oral administration of one Tenofovir Alafenamide 25 mg tablet, the blood samples will be collected in predetermined time intervals up to 6 hours. The samples will be stored in freezer -4 degrees centigrade until analysis. The concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector. The study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences. This study will be conducted without blinding.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: General Health (in terms of Liver, Heart and Kidney), Age (18-59 years old) Exclusion criteria: Smoking, History of cardiovascular, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy
-
Intervention groups
-
Intervention group will receive a single oral dose of test product (Tenofovir Alafenamide tablet of Shari Co.) and Control group will receive a single dose of reference product (Tenofovir Alafenamide tablet of Mylan Co., India). Blood samples will be taken for 6 hours at the mentioned time points and the plasma will be stored in freezer until analysis. In both groups, breakfast and lunch will be served two and six hours after drug administration, respectively.
-
Main outcome variables
-
Drug plasma concentration